Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Henit, Yanai"'
Autor:
Jacob E. Ollech, Hagar Eran-Banai, Idan Goren, Tali Sharar Fischler, Irit Avni-Biron, Yifat Snir, Yelena Broitman, Shaked Cohen, Adi Friedenberg, Maor H. Pauker, Iris Dotan, Henit Yanai
Publikováno v:
Annals of Medicine, Vol 56, Iss 1 (2024)
Introduction Real-world data on tofacitinib’s effectiveness is limited and mainly retrospective or registry-based. We elected to conduct a pragmatic prospective study to assess the efficacy of tofacitinib for moderate to severe ulcerative colitis (
Externí odkaz:
https://doaj.org/article/9ed4192db3f5459abdc38b3fc00a06b6
Autor:
Irit Avni-Biron, Ervin Toth, Jacob E. Ollech, Artur Nemeth, Gabriele Wurm Johansson, Hagai Schweinstein, Reuma Yehuda Margalit, Uri Kopylov, Iris Dotan, Henit Yanai
Publikováno v:
Diagnostics, Vol 14, Iss 16, p 1733 (2024)
Introduction: Complicated perianal disease (cPD) may be the sole presentation of Crohn’s disease (CD). The role of small-bowel capsule endoscopy (SBCE) in the diagnostic algorithm of cPD is unclear. We aimed to evaluate the role of SBCE as a diagno
Externí odkaz:
https://doaj.org/article/fd9c9713fb494a6e9a931efa8fe9ae7a
Autor:
Ayal Hirsch, Erez Scapa, Naomi Fliss-Isakov, Hagit Tulchinsky, Eran Itzkowitz, Yehuda Kariv, Yulia Ron, Henit Yanai, Ian White, Sharief Yassin, Nathaniel Aviv Cohen, Eli Brazovski, Iris Dotan, Nitsan Maharshak
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 24, p 7600 (2023)
Postoperative recurrence (POR) is the rule in patients with Crohn’s disease (CD), mitigated with prophylactic therapy. The evidence for therapeutic choice and timing of intervention is lacking. We aimed to compare the rates of POR in patients treat
Externí odkaz:
https://doaj.org/article/eb8afdd2c6274d3aa4acd2c59568af1e
Autor:
Hadar Edelman-Klapper, Keren Masha Rabinowitz, Eran Zittan, Ariella Bar-Gil Shitrit, Idan Goren, Irit Avni-Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran, Henit Yanai, Yifat Snir, Maor H. Pauker, Adi Friedenberg, Adva Levy-Barda, Yelena Broitman, Haim Ben Zvi, Tsachi-Tsadok Perets, Rami Eliakim, Revital Barkan, Sophy Goren, Dani Cohen, Iris Dotan
Publikováno v:
Vaccines, Vol 11, Iss 7, p 1263 (2023)
Vaccines are pivotal for control of the coronavirus disease (COVID-19) pandemic. Patients with inflammatory bowel diseases (IBDs) treated with antitumor necrosis factor (TNF)-α have lower serologic response after two COVID-19 vaccine doses. Data reg
Externí odkaz:
https://doaj.org/article/9af7d59e6bff4e7b8f461f8cd2945422
Autor:
Tom Konikoff, Henit Yanai, Dror Libchik, Irit Avni-Biron, Yifat Snir, Hagar Banai, Yelena Broytman, Iris Dotan, Jacob E. Ollech
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 13, p 4488 (2023)
Background and Aim: Drug sustainability (DS) is a surrogate marker for treatment efficacy. We aimed to compare the DS of two main biologics used to treat moderate-to-severe ulcerative colitis (UC), infliximab (IFX) and vedolizumab (VDZ), in a real-wo
Externí odkaz:
https://doaj.org/article/1122424cd781488a9d14085a21b92b8c
Autor:
Irit Avni Biron, Lior Hayat, Jacob E. Ollech, Hagar Banai-Eran, Bar Narkis, Ohad Houri, Maor H. Pauker, Vardit Shay, Iris Dotan, Eran Hadar, Henit Yanai
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 12, p 4120 (2023)
Background: Inflammatory bowel disease (IBD) can have an impact on pregnancy outcomes due to the effect of the disease activity and medication use. This study aimed to evaluate the pregnancy outcomes in IBD patients treated at a multidisciplinary cli
Externí odkaz:
https://doaj.org/article/df09a8ab34254d5695dcd0146575b9a7
Autor:
Olga Maria Nardone, Yifat Snir, James Hodson, Rosanna Cannatelli, Nunzia Labarile, Keith Siau, Cesare Hassan, Henit Yanai, Iris Dotan, Subrata Ghosh, Marietta Iacucci
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Advanced endoscopic technologies led to significant progress in the definition of endoscopic remission of ulcerative colitis (UC) and correlate better with histological changes, compared with standard endoscopy. However, while studies hav
Externí odkaz:
https://doaj.org/article/505cd0f67dc94be9b1b591db0522ee54
Autor:
Ahmad Albshesh, Lian Bannon, Tali Sharar Fischler, Marie Truyens, Stephan R. Vavricka, Katja Tepes, Daniela Pugliese, Edoardo V. Savarino, Eran Zittan, David Drobne, Xavier Roblin, Ariella Bar-Gil Shitrit, Alessandro Armuzzi, Triana Lobaton, Nitsan Maharshak, Henit Yanai, Shomron Ben-Horin, Uri Kopylov
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 7, p 2503 (2023)
Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effective
Externí odkaz:
https://doaj.org/article/72d070328fc64f95a65cf5be90103dd7
Autor:
Henit Yanai, Bella Ungar, Uri Kopylov, Tali Sharar Fischler, Irit Avni Biron, Jacob E. Ollech, Idan Goren, Manar Matar, Tsachi Tsadok Perets, Raanan Shamir, Iris Dotan, Shira Amir, Amit Assa
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Evidence regarding the risk of immunogenicity in patients with inflammatory bowel disease (IBD) who switched anti-tumor necrosis factor alpha (anti-TNFα) therapies to a subsequent anti-TNFα (either infliximab or adalimumab) is conflicti
Externí odkaz:
https://doaj.org/article/30e35f9753834cd797022ad1503b10ec
Autor:
Henit Yanai, Hadar Amir Barak, Jacob E Ollech, Irit Avni Biron, Idan Goren, Yifat Snir, Hagar Banai Eran, Yelena Broitman, Maya Aharoni Golan, Elena Didkovsky, Iris Amitay-Laish, Ayelet Ollech, Emmilia Hodak, Iris Dotan, Lev Pavlovsky
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background and Aims: Skin eruptions are prevalent among patients with inflammatory bowel diseases (IBD), often associated with therapies and frequently leading to dermatological consults and treatment interruptions. We aimed to assess the impact of j
Externí odkaz:
https://doaj.org/article/88b32f4454734962ae309656aa9a48f8